Adverum Biotechnologies Inc expected to post a loss of 34  cents a share - Earnings Preview

Adverum Biotechnologies

04/03/2022 22:34

* Adverum Biotechnologies Inc  ADVM.OQ   ADVM.O  is expected
to show no change in quarterly revenue when it reports 
results on March 14 (estimated). 
    * ​Refinitiv's mean analyst estimate for Adverum
Biotechnologies
Inc is for a loss of 34 cents per share. For the same quarter
last year, the company reported a loss of 39 cents per share.
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Adverum
Biotechnologies Inc is $4​, about 68.8% above​ its last closing
price of $1.25. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.31       -0.37      -0.39     Missed  -4
 Jun. 30 2021  -0.36       -0.39      -0.45     Missed  -15.7
 Mar. 31 2021  -0.38       -0.38      -0.29     Beat    23.9​
 Dec. 31 2020  -0.31       -0.32      -0.39     Missed  -20.7
 ​​Sep.        -0.35       -0.34      -0.31     Beat    9.7
 30 2020                                                
 Jun. 30 2020  -0.28       -0.28      -0.36     Missed  -27.1​
 Mar. 31 2020  -0.27       -0.27      -0.31     Missed  -13.1
 Dec. 31 2019  -0.28       -0.29      -0.29     Met     1.5
 This summary was machine generated March 4 at 22:34 GMT.  All
figures in US dollars  unless otherwise stated